The Pharmaceutical Contract Manufacturing (CMO) market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.
Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform.
In COVID-19 outbreak, Chapter 2.2 of this report provides an analysis of the impact of COVID-19 on the global economy and the Pharmaceutical Contract Manufacturing (CMO) industry.
Chapter 3.7 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 7-11 consider the impact of COVID-19 on the regional economy.
The Pharmaceutical Contract Manufacturing (CMO) market can be split based on product types, major applications, and important countries as follows:
Key players in the global Pharmaceutical Contract Manufacturing (CMO) market covered in Chapter 12:
Thermo Fisher Scientific Inc. (Patheon Inc.)
Lonza Group AG
Recipharm AB
Jubilant Life Sciences Ltd
Boehringer Ingelheim Group
Catalent Inc.
Baxter Biopharma Solutions (Baxter International Inc.)
Aenova Group
Pfizer CentreSource (Pfizer Inc.)
Famar SA
In Chapter 4 and 14.1, on the basis of types, the Pharmaceutical Contract Manufacturing (CMO) market from 2015 to 2025 is primarily split into:
Active Pharmaceutical Ingredient (API) Manufacturing
Finished Dosage Formulation (FDF) Development and Manufacturing
Secondary Packaging
In Chapter 5 and 14.2, on the basis of applications, the Pharmaceutical Contract Manufacturing (CMO) market from 2015 to 2025 covers:
Oncology
Central Nervous System
Cardiovascular Disorder
Infectious Diseases
Pulmonary Disorder
Metabolic Disorder
Gastrointestinal Disorder
Musculoskeletal Disorder
Genitourinary Disorder
Endocrinology
Others
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 6, 7, 8, 9, 10, 11, 14:
North America (Covered in Chapter 7 and 14)
United States
Canada
Mexico
Europe (Covered in Chapter 8 and 14)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 9 and 14)
China
Japan
South Korea
Australia
India
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 10 and 14)
Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Others
South America (Covered in Chapter 11 and 14)
Brazil
Argentina
Columbia
Chile
Others
Years considered for this report:
Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2025
Summary:
Get latest Market Research Reports on Pharmaceutical Contract Manufacturing (CMO). Industry analysis & Market Report on Pharmaceutical Contract Manufacturing (CMO) is a syndicated market report, published as COVID-19 Outbreak-Global Pharmaceutical Contract Manufacturing (CMO) Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020. It is complete Research Study and Industry Analysis of Pharmaceutical Contract Manufacturing (CMO) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.